Development of innovative technology for controlling high-risk viruses
Development of therapeutics for chronic hepatitis B virus
First-in-class target (HBx-DDB1) inhibitor efficacy development platform
Synthesis of effective compounds
Discovery of hit compounds by evaluating the compound library including more than 1500 compounds through the HTS system independently built by KRICT
In silico drug design, in silico virtual screening, and derivation of effective materials
Picornavirus therapeutics
Identification and verification of First-in-Class Target Mechanism
Derivation of effective materials by screening 10,000 compounds in Korea Chemical Bank
Time-of-addition evaluation to analyze the time when an effective materials starts to inhibit a virus
Verification of site of action by inducing tolerance of effective materials
Research on mutations
Efficacy study using animal models
Technology for therapeutics optimization through pharmaceutical and chemical synthesis
Development of innovative technology for treating high-risk bacteria
Research on suitable targets for developing antibiotics against high-risk Gram negative bacteria
Research on LpxC inhibition targets
Synthesis of effective LpxC inhibition compounds of new structures and verification of their efficacy
Screening of new metal binding motif through virtual screening
Structural optimization through molecular modeling
Establishment of system for measuring pharmacological activity against Gram negative bacteria and verifying LpxC target specificity
Establishment of in-house drug efficacy evaluation system
Protein purification and substrate synthesis for enzymatic assays
Development of Gram negative bacteria HTS platform design and imaging
Phase-contrast imaging-based antibiotics sensitivity test (rapid AST) and analysis of cell count
Dark field image-based analysis of shape and behavior of single bacterial cells by antibiotic effect
Development of new antiviral clinical candidates for effectively treating COVID-19
Synthesis of derivatives of effective materials for inhibiting COVID-19 infection; compound structure optimization through cell-level efficacy and toxicity evaluation; and mechanism study based on in silico modeling
Establishment of infection animal model, evaluation of in vivo antiviral efficacy using the model, and study of drug tolerance
Development of bulk synthesis method and preclinical study including in vivo pharmacokinetics and toxicity evaluation